海普瑞(09989.HK)曾重越上市價 料中績最多賺6億人幣
海普瑞(09989.HK)(002399.SZ)料中期純利最多增長10%,A股今早曾高見28.63元人民幣,現造28.32元人民幣,急漲8.8%,成交2,512萬股;H股曾重越上市價18.4元,最高見18.54元,現造18.12元,回升3.1%,成交增至1,000萬股,已遠超昨天全日成交量452萬股。
海普瑞預計,上半年純利介乎5.46億至6.01億人民幣,按年增長0%至10%,主要受惠於由於垂直一體化肝素特許經營產業鏈受依諾肝素注射液製劑業務驅動業績快速增長,原料藥業務毛利率也實現大幅上升,CDMO業務收入增長、毛利額及毛利率增長,邊際效應顯著;及非經常性損益下降75%-85%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.